Cell-to-cell variability in inducible Caspase9-mediated cell death

Area of Science:

• Cellular and Molecular Biology
• Immunotherapy
• Pharmacology

Background:

• The inducible Caspase 9 (iCasp9) suicide gene is a key component in cell therapies for targeted cell elimination.
• Significant heterogeneity exists in cellular responses to apoptosis inducers, complicating clinical applications of iCasp9-based strategies.
• The underlying causes of this cell-fate heterogeneity and subsequent drug resistance remain largely unknown.

Purpose of the Study:

• To elucidate the sources of cell-to-cell variability in iCasp9-mediated apoptosis.
• To investigate the mechanisms of drug resistance development during repeated iCasp9-targeted treatments.
• To identify strategies for overcoming drug resistance and enhancing therapeutic efficacy.

Main Methods:

• Simultaneous single-cell monitoring of iCasp9 dimerization dynamics, Caspase3 activation, and cell fate.
• Analysis of cell-to-cell variability in initial iCasp9 expression and the XIAP/Caspase3 ratio.
• Evaluation of single-round versus multiple-round drugging efficacy and resistance development.
• Assessment of combinatorial therapy with XIAP inhibitors to overcome resistance.

Main Results:

• Cellular heterogeneity in iCasp9-mediated killing is primarily driven by variations in initial iCasp9 expression levels and the XIAP/Caspase3 ratio.
• Multiple rounds of iCasp9-targeted drug treatment do not improve killing efficiency and instead induce drug resistance by imposing selective pressure on protein levels, particularly initial iCasp9.
• Combinatorial treatment with a XIAP inhibitor, administered at the conclusion of multiple-round iCasp9 treatments, effectively mitigates drug resistance.

Conclusions:

• The study identifies specific molecular factors contributing to cell fate heterogeneity and drug resistance in iCasp9-based cell therapies.
• Understanding these mechanisms is crucial for developing more effective and robust therapeutic strategies.
• Timing of combinatorial XIAP inhibition is critical for overcoming drug resistance in iCasp9-mediated cell death, offering a potential optimization for clinical applications.